OpenURL Connection Search

Select item for more details and to access through your institution.

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 559, doi. 10.1002/hon.6_2632
By:
- Dickinson, M.;
- Popplewell, L.;
- Kolstad, A.;
- Ho, P.J.;
- Teshima, T.;
- Dreyling, M.;
- Schuster, S.;
- Thieblemont, C.;
- Ghosh, M.;
- Riedell, P.;
- Yateman, N.;
- Lehnhoff, K.;
- Lawniczek, T.;
- Pacaud, L.;
- Fowler, N.
Publication type:
Article
INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 505, doi. 10.1002/hon.189_2631
By:
- Jaeger, U.;
- Tam, C.;
- Borchmann, P.;
- McGuirk, J.;
- Holte, H.;
- Waller, E.;
- Jaglowski, S.;
- Andreadis, C.;
- Foley, S.R.;
- Fleury, I.;
- Westin, J.;
- Teshima, T.;
- Mielke, S.;
- Salles, G.;
- Ho, P.J.;
- Izutsu, K.;
- Schuster, S.;
- Bachanova, V.;
- Maziarz, R.;
- Van Besien, K.
Publication type:
Article
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 308, doi. 10.1002/hon.118_2630
By:
- Bachanova, V.;
- Westin, J.;
- Tam, C.;
- Borchmann, P.;
- Jaeger, U.;
- McGuirk, J.;
- Holte, H.;
- Waller, E.;
- Jaglowski, S.;
- Bishop, M.;
- Andreadis, C.;
- Foley, S.R.;
- Fleury, I.;
- Teshima, T.;
- Mielke, S.;
- Salles, G.;
- Ho, P.J.;
- Izutsu, K.;
- Maziarz, R.;
- Van Besien, K.
Publication type:
Article
ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 559, doi. 10.1002/hon.6_2632
By:
- Dickinson, M.;
- Popplewell, L.;
- Kolstad, A.;
- Ho, P.J.;
- Teshima, T.;
- Dreyling, M.;
- Schuster, S.;
- Thieblemont, C.;
- Ghosh, M.;
- Riedell, P.;
- Yateman, N.;
- Lehnhoff, K.;
- Lawniczek, T.;
- Pacaud, L.;
- Fowler, N.
Publication type:
Article
INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 505, doi. 10.1002/hon.189_2631
By:
- Jaeger, U.;
- Tam, C.;
- Borchmann, P.;
- McGuirk, J.;
- Holte, H.;
- Waller, E.;
- Jaglowski, S.;
- Andreadis, C.;
- Foley, S.R.;
- Fleury, I.;
- Westin, J.;
- Teshima, T.;
- Mielke, S.;
- Salles, G.;
- Ho, P.J.;
- Izutsu, K.;
- Schuster, S.;
- Bachanova, V.;
- Maziarz, R.;
- Van Besien, K.
Publication type:
Article
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 308, doi. 10.1002/hon.118_2630
By:
- Bachanova, V.;
- Westin, J.;
- Tam, C.;
- Borchmann, P.;
- Jaeger, U.;
- McGuirk, J.;
- Holte, H.;
- Waller, E.;
- Jaglowski, S.;
- Bishop, M.;
- Andreadis, C.;
- Foley, S.R.;
- Fleury, I.;
- Teshima, T.;
- Mielke, S.;
- Salles, G.;
- Ho, P.J.;
- Izutsu, K.;
- Maziarz, R.;
- Van Besien, K.
Publication type:
Article
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS.
Published in:
Hematological Oncology, 2017, v. 35, p. 27, doi. 10.1002/hon.2437_6
By:
- Schuster, S.J.;
- Bishop, M.R.;
- Tam, C.;
- Waller, E.K.;
- Borchmann, P.;
- Mcguirk, J.;
- Jäger, U.;
- Jaglowski, S.;
- Andreadis, C.;
- Westin, J.;
- Fleury, I.;
- Bachanova, V.;
- Foley, S.R.;
- Ho, P.J.;
- Mielke, S.;
- Holte, H.;
- Anak, O.;
- Pacaud, L.;
- Awasthi, R.;
- Tai, F.
Publication type:
Article

Found: 7

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.

INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL.

CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS.

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.

INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL.

CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS.

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS.